Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Operating Expenses (2018 - 2025)

10x Genomics' Operating Expenses history spans 8 years, with the latest figure at $132.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 17.54% year-over-year to $132.6 million; the TTM value through Dec 2025 reached $504.9 million, down 17.1%, while the annual FY2025 figure was $504.9 million, 17.1% down from the prior year.
  • Operating Expenses for Q4 2025 was $132.6 million at 10x Genomics, roughly flat from $132.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $190.3 million in Q3 2023 and bottomed at $95.0 million in Q2 2025.
  • The 5-year median for Operating Expenses is $143.6 million (2022), against an average of $141.1 million.
  • The largest YoY upside for Operating Expenses was 67.77% in 2021 against a maximum downside of 73.8% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $131.8 million in 2021, then rose by 8.15% to $142.5 million in 2022, then increased by 19.98% to $171.0 million in 2023, then fell by 5.95% to $160.8 million in 2024, then decreased by 17.54% to $132.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Operating Expenses are $132.6 million (Q4 2025), $132.5 million (Q3 2025), and $95.0 million (Q2 2025).